Efficacy and Safety of Lenalidomide (LEN) Plus Low-Dose Dexamethasone (DEX; Rd) in Chinese Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) According to Disease Stage (international Staging System [ISS]): Results from the MM-021 Trial and MM-024 Extended Access Program (EAP)

J. Hou,Z. Cai,J. Jin,F. Chen,D.B. Zhou,L. Yu,X. Ke,X. Li,D. Wu,F. Meng,D. DeMarco,J. Zhang,J. Mei,X. Du
DOI: https://doi.org/10.1016/j.clml.2015.07.599
IF: 2.822
2015-01-01
Clinical Lymphoma Myeloma & Leukemia
Abstract:In a multicenter phase 2 trial evaluating Rd (LEN 25 mg/day on D1–21 and low-dose DEX 40 mg/day on D1, 8, 15, and 22 of each 28-day cycle) in 199 Chinese pts with RRMM (MM-021), overall response rate (ORR; defined as complete response, very good partial response, and partial response) was 47.6%, median duration of response (DOR) was 8.8 months (mos), and median PFS was 8.3 mos (Hou J, et al. J Hematol Oncol. 2013;6:41). Long-term safety of Rd was confirmed in the MM-024 EAP (Du X, et al. Blood. 2014;124:abstract 5737). Disease stage according to the ISS predicts outcomes in newly diagnosed multiple myeloma (MM) pts (Greipp PR, et al. J Clin Oncol. 2005;23:3412-20). Here we report outcomes by ISS stage in RRMM pts in the MM-021 and MM-024 studies.
What problem does this paper attempt to address?